ᐈ Abzena taps into ProteoNic’s viral vector tech

🔍 Abzena has partnered with ProteoNic to use its viral vector technology in the development of biotechnology products. 🧬 This technology is used to deliver genetic material into cells, making it an important tool in gene therapy and biopharmaceutical manufacturing. 💉 The partnership will allow Abzena to enhance its capabilities in viral vector manufacturing and offer a more efficient and streamlined process for its clients. 🚀 This collaboration highlights the growing importance of viral vector technology in the biotech industry.

📢 Abzena taps into ProteoNic’s viral vector tech

Introduction:

Abzena, a contract development and manufacturing organization (CDMO), has signed a licensing agreement with ProteoNic to use its viral vector production platform, 2G UNic technology, for the development and manufacturing of gene therapies. Viral vectors are commonly used in gene therapies to deliver the therapeutic genes into target cells.

Main points:

Abzena has signed a licensing agreement with ProteoNic to utilize its viral vector production platform, 2G UNic, for gene therapy production.
The 2G UNic technology improves gene therapy production by increasing the yield and potency of viral vectors.
This technology is expected to enable Abzena to meet the increasing demand for viral vectors for gene therapy applications.
ProteoNic’s platform has already been validated in clinical trials, demonstrating its effectiveness and safety.
Abzena’s collaboration with ProteoNic highlights its commitment to providing high-quality gene therapy manufacturing services to its clients.

Conclusion:

Abzena’s partnership with ProteoNic and utilization of the 2G UNic viral vector production platform showcases its dedication to advancing gene therapy manufacturing. This technology has the potential to significantly improve viral vector production, thus meeting the growing demand for gene therapies. By incorporating this platform into their processes, Abzena is positioning itself as a leading provider of gene therapy manufacturing services in the biotechnology industry.